<SEC-DOCUMENT>0001144204-14-048314.txt : 20140812
<SEC-HEADER>0001144204-14-048314.hdr.sgml : 20140812
<ACCEPTANCE-DATETIME>20140811113721
ACCESSION NUMBER:		0001144204-14-048314
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140811
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140811
DATE AS OF CHANGE:		20140811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-119366
		FILM NUMBER:		141029482

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v386369_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report: August 11, 2014<BR>
(<I>Date of earliest event reported</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B><BR>
(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P></TD>
    <TD STYLE="width: 5%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>333-119366</B></P></TD>
    <TD STYLE="width: 5%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>04-3321804</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>of incorporation)</I></P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Commission</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>File Number)</I></P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(IRS Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3301 Agriculture Drive </B><BR>
<B>Madison, WI 53716</B><BR>
(<I>Address of principal executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(608) 441-8120</B><BR>
(<I>Registrant&rsquo;s telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 7.01</B></TD><TD STYLE="text-align: left"><B>REGULATION FD DISCLOSURE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2014, we issued a press release announcing that
we had submitted an Investigational New Drug (IND) application to the U.S. Food &amp; Drug Administration (FDA) to begin clinical
study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed/refractory multiple
myeloma, an incurable cancer of plasma cells. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 9.01</B></TD><TD STYLE="text-align: left"><B>FINANCIAL STATEMENTS AND EXHIBITS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD>Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 5%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated August 11, 2014, entitled &ldquo;Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">Dated: August 11, 2014</TD>
    <TD COLSPAN="2"><B>CELLECTAR BIOSCIENCES, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ Chad J. Kolean</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name:&nbsp;&nbsp;Chad J. Kolean<BR>Title:&nbsp;&nbsp;&nbsp;&nbsp;Vice President and Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 5%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated August 11, 2014, entitled &ldquo;Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v386369_ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><B>Cellectar
Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple
Myeloma </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, Wis., August 11, 2014,</B>
&ndash; Cellectar Biosciences, Inc. (OTCQX: CLRB), announced that it has submitted an Investigational New Drug (IND) application
to the U.S. Food &amp; Drug Administration (FDA) to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting
radiopharmaceutical, in patients with relapsed/refractory multiple myeloma, an incurable cancer of plasma cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Despite the emergence of new treatment
options, no cure exists for multiple myeloma and the limitations of available therapies are particularly evident in patients that
have relapsed or become resistant to treatment creating a clear need for the development of additional novel therapeutics,&rdquo;
commented Dr. Simon Pedder, president and chief executive officer. &ldquo;The radiosensitivity of multiple myeloma has been well
established and preclinical models show pronounced uptake of our phospholipid ether (PLE) analog delivery platform and significant
therapeutic response to a single dose administration of I-131-CLR1404. We believe the&rsquo; selective nature and prolonged retention
of our agent could enable effective, localized treatment to suppress or eliminate malignant plasma cells while preserving the important
functions of normal blood cells.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Multiple Myeloma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Multiple myeloma is the second most common
hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the U.S., approximately 70,000
people are living with multiple myeloma and approximately 24,000 new cases are diagnosed annually. Worldwide, nearly 230,000 people
are living with multiple myeloma and approximately 114,000 new cases are diagnosed annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar Biosciences is developing agents
to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as
a targeted delivery and retention vehicle, Cellectar&rsquo;s compounds are designed to be selectively taken up and retained in
cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery
platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer
cells to &ldquo;find, treat and follow&rdquo; malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum,
cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored
Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted
molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells.
A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of
2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted,
non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional
information please visit www.cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kate McNeil, Vice President of IR, PR &amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (347) 204-4226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: kmcneil@cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains forward-looking
statements.&nbsp; You can identify these statements by our use of words such as &ldquo;may,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plans,&rdquo; or
their negatives or cognates.&nbsp;&nbsp; These statements are only estimates and predictions and are subject to known and unknown
risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.&nbsp;
These statements are based on our current beliefs and expectations as to such future outcomes.&nbsp; Drug discovery and development
involve a high degree of risk.&nbsp; Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA
review process and other government regulation, our&nbsp;pharmaceutical collaborators&rsquo; ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description
of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange
Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the
date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!*`1<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_***X#]I
MG]I[P7^R'\)-0\:^.]7CTG1;#"*`-]Q>S$'9!!&.9)6(X4>A)(4$C2E2G5FJ
M=--R>B2W;!NVK._KSSXE_M;?##X.:]:Z3XH\?^$M$U>^N([2"PNM4A6[EED8
M(B"'=O)+$`<=Z_$#]NG_`(+E?%G]K'4KW2O"U]>?#3P*Y,<=CIEP4U*]CY&;
MFZ7Y@2#S'$54="7ZU\K?`(A_VB?`D\K%YI?%&F-)*YW.Y-Y%R6/)/N:_2LO\
M-ZTJ+K8ZIR.U^5:OYO;[K^IRSQ2O:*/ZJZ_/7_@XD_:R\9_LS_LZ>";+P)XG
MUCPIK?B?79#)>Z9/Y%RUO;V[.T8<<@&1X<XZXP>"0?T*K\__`/@L3^Q=>?MJ
M?&WX2Z;%KT6G6V@.S26KQ%Q/]HN8%<Y'0[(2/QKX/)\SR[+\=2Q6:24:2>MT
MVKM-15DGN[=#3$2Y8,^V/@A-J\_P7\(2>(+EKS7I-%LVU*=D"&:Y,">:Y`P`
M2^XX`P,UL>+/%NF>`_#&H:UK6H6FE:1I4#W5Y>74HBAMHD&YG=CP%`&<FF^*
MO%6E?#SPG?ZSK%]::3HVCVSW-W=7#B.&UA1<LS$\``"OQL_:=_:D^)G_``78
M_:)3X/\`P>ANM'^$VDSK<7]_<(\<5U$KX%]>XY$>03#;?>=@&;D?N^S*,GGF
M-6=234*4=9R>T5V7GV14ZG*K;L^\OV$_^"N'A']OS]H'QOX*\)^&O$%MIWA6
MU%]::[<;3;:I#YHBW%``T!9CN17R70,?E*E:^LZ\C_8K_8K\%_L*_!>T\'>#
MK0\D3ZGJ<Z@WFL7.,-/,P[]E4?*BX`&.OKE<6:SP<L3+ZC%QIJR5W=NW5]K[
MVZ%0YK>]N%%%%><4%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`4O$OB2P\&^'-0UC5;N&PTS2K:2[N[F9ML=O#&I=W
M8]@J@DGT%?S>?\%+O^"@.M_\%!?VA+O7I9KJV\%Z*\EKX7TIB52UMLX-PZ]/
M/FP&8GE1M0<+S^J?_!Q5^T?<?!_]B.V\(:?.T&H?$[4UTN4J<-]AA7SKD9]&
MQ%&?592*_#[X;?#S5OB[\1=`\)Z%#]IUOQ-J,&EV,9Z---($4G_9!.2>P!K]
M@\.\GITZ$LTK+5W46^B6[^>WHGW.+$S;?(CV/]@'_@G3X[_X*%?$>;2O#2QZ
M5X>TEE_MKQ#=QEK73@1D1JHP99V'*Q@CCEBJ\G]KOV4/^",7P(_94MM/NX?"
ML'C'Q19,DO\`;GB)5O9Q*N"'BB(\J'##*[$!''S$C->Q_LB?LN>'?V-_V?O#
MWP_\,PJMGHT`^T7)0++J-TPS-<R>KR/D^PPHX4"NV\7^,],\!Z))J&K7<=I:
MQG&YN6=NRJ!RQ/H*^0XIXWQ&+G/V=3V="-^MKKO)^?;9>NIK3I1@KR-2O*?B
M!\);J\^-^G^,KS4+"WT+2(DEF\UBKQ>6&/IC!8@YR._%55_;2\,&_P#+-EK0
M@SCSO)0CZ[=V<?K1\7O#6J?M%:5HC^&-8LI/#DSG[9EBI5P1AF7&6*C/R'&#
M@^X_'<TS3`9CAFL(_;SIN,E"+LVT]&^\4WKTL34J0G'W=6NAY=^T#:ZC^WM:
MZCX#TP/:>&9U_>S2*=O!XFE'<9&5C[GD\_=]<_8\_8W\$_L0_"&W\(>"K#R(
M2_VB_OI0&N]5N"/FFF?N>P7[JJ`H``IWBKP/K_PE^'VGZ;\/+.*6X>?_`$V:
M0(T\F5_UAWD*23^0Q@8KP;]K#]D/X\_M2?!^[\/Z=\0'\&W]W,CFY&IS0`(#
M\RD6H!(([9Q77P_CL=AZZRS'2J2=:<93DE^ZA=65M=5%;^9$.:$KR3<G]Q]9
M>*?B1X=\#20IK>OZ+H[W+K'$+Z^BMS*S'"JN]ADD\`#K6U7Y3^!O^#8/2M8O
M(KWXC_&#7]?N'8-<1Z;IRPO(,\CSYWE?GUV@U^J&D:7%H>DVME!O\FSA2"/>
MQ=MJJ%&2>2<#J>M?>YKA<!0Y5@Z[JO6_NN*6UK7=WU.J$I/XE8L45XW\=OV[
M?`'P%\;0^$KF?6_%'CBYC6>/PQX8TR75]6$9Z2/%$"(4/9I60'MFN3N?^"D5
MGX9A-YXJ^#WQW\):.GS2:I>^%/M5M;)_?E%I+-(BCOE..]<]/+,5.*G&#L]N
ME_1/5_*Y3DCZ0HKGOA9\6/#7QN\"V'B;PCKFF^(M`U--]M?6,PEAD&<$9'1@
M>"IP0000#70UQ3C*$G&2LUT'<****D`HHHH`****`"BBB@`HHHH`**BO;^#3
M8#+<S101+U>1PBC\33K>YCNX5EBD26-QE71@RM]"*?F`^BBBD`4444`%%%%`
M!1110`4444`?C5_P=!>(KB?XU_"322[?9;71-0O%7/&^2>%"?KB,5\[_`/!"
M?P?:^,/^"GW@`7B+*FD6VHZG&K=/-CM)%0_4&3/X5]5?\'0_PWF6_P#A!XR1
M&:`C4-#G8#A'/E3Q`GW"S?\`?)KXB_X).?&ZU_9]_P""A_PP\0:A-';Z;<ZD
MVC7DLAVI%'>1/;!V/8+))&2>P%?NV2IU>%'"COR5%\[R."H[5M>Z/Z4*^5_V
MO?$]SJ_Q6;3G=OLNDP1K%'_#N=0[/]2"!]!7U17A'[5_P2O]?U%/$ND6\EY(
ML0BO;>,;I"%^[(H_BP."!S@`^M?RMQ[A<3B,JE'#)NTDY);N*O\`?9V?R-<9
M&3I^Z?/5>N?L;^*+C3/B5/I0=C::I;.[IGY1)'@A_K@D?EZ5Y*()&N!"(Y3,
M3CRPAWY],=<U]&?LH?!.^\*33^(M8@>UN;B+R+2WD&)(T)!9V'\).``#SC.>
MM?E'!N$Q-7-J4\.G:+O)]$NM_5:?,\W"QDZB<>A[=7S+^T-_P5\^!/[+7Q>U
M7P+XT\3ZEIWB31EA:ZMXM%N[A$$L2RIAXXRIRCJ>#QG%?35?S*_\%)?C9;?M
M$?MX?%+Q98SK<Z;>:V]I8S+RLMO;(MM&X]F$.X>S5_77!W#]+-<3.&(;4(QO
M=66K:MNGTN>M7JN"5C]^OV1O^"BGPI_;CU;7+'X<ZY>ZO<^'(89[Y9],N+,1
M)*SJA!E10V2C=,XQ7;?M/_%F3X#_`+-_CWQK#$)[CPIH%[JL,;#*R20P/(BD
M>A91GVK\X?\`@UZ^',UKX&^+GB^6)Q!J.HV&CV\A'#F"*260#Z?:(Z_3[XD^
M`=/^*OP[U[POJR-+I?B/3Y],NT'!:*:-HW`]]K&N#/<#A<!FLL-3O*G!QO?5
M[)M:)>:*IR<H79Y!_P`$Z/V?-/\`@E^S5H.IRL-4\:>.[2'Q'XKUZ<;[S6M0
MN8Q-(\DAY*(7V(N=JHH``YS[S7QQ^SI^UPO[$?A'2OA%^T%/-X5O?"<2Z5H/
MC2ZA<:!XKL(@$MY/M0!2"Y$059(I2IW*2"P:O6?%_P#P4F^`7@C1S>WOQ?\`
M`,T9&4BL=8AOKB8]@D,!>1R>P5236&88'&5<3*HHN?,VTTFTUTM;I;ITVLK6
M*4DD>D?#SX,>%?A+J&O77AG0=-T.;Q1?'4]5^Q1");VY*!#,RCY=Y"C)`&3R
M<G)KXP_;.TSX3^)?^"F]EI_QI\1VFA^%(OAC%<6`OO$T^B6SWO\`:LRY#1S1
M;W\K=P2>!TXKZJ_9A^/^I?M'^$=0\0S^!_$?@O1FO3%HAUQ5@O-8M`JD79MO
MOVZLQ8*DGS%0&P,XKYK_`&E/BY\+O@Y_P57AU#XL:CX:TW0[OX4Q6]G)K<"R
MP/<?VO*VU0RL`^P,?IFNG*8UXXNI&?,YJ+^%WETV:OJMO+8F5K(9X!_9H_8I
M^*OBZS\/^&?%.A>(-<U`L+6PT_XE7]Q<W!5"[;$2\+-A59C@<`$U]=?!OX->
M'_@%\/K/POX7M;FRT6P:1X89[V>\D4R.7;,DSO(<LQ/+''08%?/>A_\`!07]
MD#PQJL5_IOC?X5Z??09\JXMK2.&6/((.&6,$9!(X/0U[[\$OC[X-_:/\&-XB
M\#>(M/\`$^B+<O9F\LG+1"9`-Z9('(W#\ZRS5XUQ3JJKR?W[M7U[I+;Y[CC;
MI8\9_P"">6H7-]XW_:-6XN;FX%O\6-1BB$LK.(D%G9$(N3\J@D\#`Y-?2M?"
M/[+?[;GPF_9H^,'[1.B>/?'N@^%]7O/BEJ%[#:7TC)))";6S02#"D;2R./JI
MKW'0/^"I?[/7BC7K'2]/^+/A.[U#4[B.TM8(YV+SRR,$1!\O4L0!]:K-,MQ<
MZ[J0I2<;1U47;X5UL$9*VYB_M^:A<V7QF_9E2"YN8$N/B;'',L4K(LR?V9?G
M:P!^9<@'!R,@5]+U\E?\%1OB!HOPI\:?LY^)/$>I6^D:%HOQ)CN;Z]N"1%;1
M_P!F7PW,0#@9('XUUO\`P]H_9O\`^BP^#_\`P(?_`.)J*N!Q%?"4)4*<I*TM
MDW]I]D',DW<^B*_+7]DCPC^RQXP^&FKWWQ?\<:+9^.W\5:\EY#J7Q!N].N(X
MEU2Y6`&%;I`H\H)C"C(P:_1OX)?'WP;^TAX,;Q%X%\1:?XGT1+E[,WEDY:(3
M(`73)`Y`9?SKX/\`V#?VIOV;/A?\#]1T;XD:_P##JQ\6VWBWQ"UU#JUE')=H
MC:O=M'N9HR2"A4CD\$?2NO*(5Z="O&,:BDI034+J2TGOHW;OYV%-JZ/9/@E^
MP]^RK\9WDU;P!=P^+%T*[B,T^D^/=2OH[688D17V7;*#P#M;J.Q%>T_MJ_M%
M/^RE^S#XL\=06"ZKJ.D6R1Z;8LVU;R]GE2"WC8CD*9I$SCG&:\T\+?\`!2_]
ME/P+!-%HOQ(^'6CQW#!Y4L4%NLK`8!8(@R<<9->B?MJ?`&7]K3]E3Q1X.TR_
MAL-3U>VBN](O9%+107D$J7-M(V.=GFQIG'.TFN:O[9XND\P4_9\R_B7O:ZYN
MWSL-6L^4\U^''_!,;POXQT>VU[XZ27'QA^(>H1B?4KK6KB232["5N6M[*R#"
M"&!"=J_(68#).3@:\7_!-WPO\,/%.G:_\'M7U?X0ZK:74<EW;:5+)<Z-K$`8
M>9!<:?*_DG<N0LD>QT)!!.,'.^%W_!4#P18Z=;Z%\8[A?@U\1K!!#JND>)`;
M.UDF48:6TNF'D7%NYRR,CDX(R`:T;S_@IO\`#[Q=XRTKPS\+QJ/QB\1:E=Q0
MS0>%H_/L]+@+@27-S>-BWB1%);!<LQ`4#)S6M3^V>=IJ7+_Y3M_Z1R]N@O</
M1OVA?V4/`_[4MKI,/C;3;_48]$>22S%MJUYIYC:0*')-O+&7R%'#9QVQDU\>
M?%7_`()Z_"SPW_P4"^$7@BRTKQ##X9\4>'=?OM3LO^$IU1A<S6QL_(?<;C>N
MWS9.%(!W<YP*_0FOF'XY?\I6/@'U_P"12\5?ST^L<GQ^)A*5*%22BH5&DF[)
M\DG>WKKZZCFEO8[_`.!'["7PS_9K\:2^(/!^CZI8:K/:O9/)<:]J%\AB9E8C
MRYYG0'*+\P&1CKR:R?\`@H'^T)J_P0^"L&E>#PEQ\2_B)?1^%_!]L3DB^N`0
M;EAVCMX@\S'H!&`>M>ZLVT$DX`Y)/:O@SP]X/^)?[??[4FJ_&SP%XTT+P?X4
M\!RW?@_P1-JGA\ZQ'J2!@NH:E"AFB">9,AA209+1Q$<`G,Y??$UWBL9.\8*[
M<FVF_LQ>[U>Z7V4V$M%9'0_LN>#K[_@F]^TYI/PDU37]9\0>`_BOIRWGA[5=
M6NGN);?Q#:PJ+^U9W8D"ZC47"+G`9)%45]I5\5_M)?L+?M$_'[X=+I^J?&[P
M7?7NB7D.N:*UOX&^PW%MJ-LWF6\D<XNF,1WC:6VGY'8$$$BO?_V+OVDX_P!J
MK]GS1O%$UHVEZ]$9-,\0Z6XQ)I&J6[&*ZMF!Y&V125SU1E/>KS:"K4XXR,U.
M6TW&^_V7JH_$E9Z;IMO4(NVA\J?L._L._#+]I7P'XV\4>.++6]6UZ3X@^);0
MS_\`"3ZE;`11:G.D:!(KA4`50`,#M7I'Q7_X)E?`;P'\.-:UN'4/$W@&;2;2
M2[C\0VOC?4XI=)9%+"8&2Y9#M(SA@0>F.:\X_8)_8"^#W[1?PZ\;^)_&O@;3
M=?UZ;XB>)[>2\GFG1W2/59U1<(ZCA>.E,_;$_P""8GP^_9YU'PY\7?`/PQTS
MQ)I'@:4R^*O!,T<E]!K6FDYDNK>*5F!O+;'F(IR)%5E(SC/MUL5S8^5!8JI%
MW:2M[M^D4^>UGLFXV[JQ"7NWL?3/_!.GXH^)_C5^P]\,_%/C(R2>)-:T6*>\
MFDB\I[OEE2<KV,L823T^>BO2_A=X^T'XI_#G0_$?A:]M-1\.:U917>G7%MCR
MI(&4%-H'3`XV\$$$$`C%%?&XR?-7G)1Y;M^[VUV^6QJMCPW_`(*P?LAS?MI?
ML2^*?"VFPB?Q-IH36]!7H7O;?++$/^NJ&2+_`+:Y[5_-O+$Z,\<B2PRQL4=&
M!22)@<$$=58$8]017];%?CW_`,%QO^"0^HZ7XGUCXW?"W29K_3M1+7GBW0[.
M,O+:2]7U"!!RR-UE0#*MF09!?;^C>'W$=/#R>78F5HR=XM[*75?/2WGZG-B:
M=_>1]._\$8_^"I>F?MC?"FP\#>+=2BM_BOX7M!#.D[A6\16T:X6\BS]Z3:!Y
MJ#D-EONL,?<]?R8>'?$5]X9UJQU?2+^[T[4M/E6YL[VSG:&>VD4Y5XY%(*L/
M4&OT-_9>_P"#C_XH_"C2;72OB+X>TSXDV=LH0:@DW]FZH5`P-[*K12GWV(3W
M)/-=/$GA]6E6EB,LLT]7!NUGY-Z6\G:W2XJ>)5K2/V^%I$)S+Y4?FG^/:-WY
MU)7YAO\`\'0'P]&E[U^%OCPWN/\`4F[LQ'G_`']^<?\``:^;_P!JC_@XR^*_
MQDTFZTCX?Z+IOPQTZY!1KY)O[0U;:1@[)&58XC[JC,.S`\U\OA.!,XJSY'2Y
M%U;:M^#;?R1K+$074^S/^"V__!4O3?V7_A7J7PR\&:I%<_$[Q5:M;7+6[ACX
M:LY%P\\A'W9W4D1)]X9\PX"KN_"K3]/GOKFWL[.WFNKJYD2WM[>%2\D\C$*D
M:CJ69B`!W)%/UC6+G6=2N]1U&\N;V^O96GN;JYE:6:XD8Y9W=B69B>I))-?K
M3_P0U_X)#ZCH6O:5\</BGI4MA/:@7/A'0;N/;-&Q'&H7"'E&`/[I&&X9WD`[
M,?J-&E@N%\L<I/FD_DYRZ)=DOP5WN<C<JLS[O_X)G_LFG]BW]C+P?X(NEC&N
MI`VHZXZ<A[^X/F3#/<(2(P>ZQK7O5%<G\>I6@^!GC1T=HW30KYE=20RD6[\C
M'<5^%5J]3%XF56J_>F[M^;9Z'PJR.EU32K76["6TO;:"\MIAMDAGC$D;CT*G
M@CZUSOAOX&^"?!NJB^T?P?X6TJ^!W?:+/2;>"7/KN1`<_C7QK\&_V=)]>^#'
MA2_/[.]KK4M[HMI.=1D^(<EN]^6@1O.*]4+D[L=LX[5TVH>*+K6/^"6NEFXU
M>_U#5-+UBPTR]FFE9IH)X=<BB>W,FXF01;?*$FX^8J!OXL5ZDLL<&J=.KHY*
M+VZWU]V<NW6WYVCVG='V;5:?3;/4W$DL%M<,ORAF17(]LFO!/VG]OQ`_:5^'
M?P^\1ZG>Z5X$U^PO[V>&WNGM%\0WT+0B*QDE0JVP1O)+Y88>9LP<A2*YK]H7
MX.^%OV3&\(^)/AI"?"OBR]\1:?I<&D6%S(+?Q-#-<(D]O+;EBK[8B\GF!=R&
M/.[&:XZ.!C+DBYM2FKK33=K5WTVULG;KULW/?R/IQ]`TV-2S65DH'4F%`/Y5
M9M+2&RBV011Q(3G;&H49]>*^9OVC_@!KWQ+_`&A+O6(--\$_$S2K?2K>W3PO
MKNM3V3:')ND+3I'&DD;><"N6D0,/+`4XS5K]E;5[7X8?$;Q;X#3P!=>"?$ZZ
M/'X@CTRW\1OK&DW$.]X5,.XC[.QDX*>6FX8/(%.6!3H>TC.[LFUII]\N;2^_
M+;Y:AS:VL?0]QHUA),7EM+-I)3RSQ*68_B.32IX?L(W5A96@93D$0J"#Z]*^
M7OV3_P!GSP-^U%\%--\<^/(/^$Z\9ZZ9)-8GU&ZE=M(N@[![**$,%MEA(V!5
M"M\N223FNT^(_AS1/`G[$'Q1TSPQXCO]>T_3=$UB*.2?5O[1ETUUMY,VHFR7
M`B/`5V++T)Z45<'&-7V"FW)247IIO;1W^ZZ5P4KJY[G=V,-^@6>&*=5.0)$#
M`'UYJ#_A'-/_`.?"S_[\+_A7RK^U=I%SXJ_9_P#@%ID.G1Z]+JFM:9"VG7&H
MR6,.H@Z9<,8Y)T!95XSG!Y4<5V/[.'[)^E^'/%1US6_AAH7@[5='D272Y]/\
M4WFK>8Q5U<LLBQJN`0!D-G<>F*<L%"%#VLZCOKHDNCMUDG]R=@YVW:Q]`VMG
M%8Q%(8HX4)SM10HSZX%5V\/6#L6:QLRS'))A4D_I7RSXK\$^+=<_;:^)OB/P
M1JLT/BGPCI&AR6FF75RRZ9K<$J71GLYEZ(7\M"DH&8W4$Y4L*V?A9\<+#XY_
MMJ^&]2TXWUD\'@;4[74])NR8[G2;V/4+19()XL_+(IR`>C*05)4@TY9;)1YX
MRNN7F?DW'F2?JMGZASGT8^@:;&I9K*R`'<PH!_*KH&`!Z5\N_"GX6^&_VK/B
MO\3;OXE*WB36?#'B6XTBR\/7MRXM-%L$5#;RI;!@K-.K>89F!+9P"`N*];^#
M/PL\(_![5O$>C^$]8NO+412W&@-JQO(=%)5MK1Q.6>`2#)VYVG;E0.:QQ&&A
M3O%R;DDGMIK;K?SWM9_<-2N=YK7A^P\1VOD:C8VE_#G/EW,*RI^3`BG:5HUI
MH5H+>RM;:S@7D1P1+&@_``"O@S]D3]FF?XE?";PAJFI?";P[KNGZH=UUKUSX
MVO8;R>(SL&F-LL94.%!P@?!P.1GCZ!_:>_9\FU3X3>#O"'@Z\T33M.TG4T8>
M'-5U.XM;7Q%;I%)_H;3(3,<$B3'S`^7\P(KIQ&7TJ598?VO5IZ*RMZ2>OD[>
M;1*FVKV/>DD$@RK!AZ@YIK6Z/,DK(AD0$*Q4%E!Z@'MFOD'PIX?M/V9_B[X.
MU/Q!\'M.\#KKFK1Z%:ZEX5\62W%L]Q<*R1I<696+S4)R=Q5]A`;'&:^P:XL9
MA51:Y7=-;Z?I*2_'Y%1E<",@@\YIEO;QVD*Q1(D<:#"JBA57Z`4^BN.Y04R&
MVCMRYCC1#(V]]J@;F]3ZGWI]%%P&06\=LI6-$C#$L0J@`D]3QW-/HHHN`RVM
MH[.%8H8TBC7HB*%4<^@HI]%#8!1110!\%?MV_P#!`SX:_M1:K?>)O!-S_P`*
MS\97C-+.;2V$NDZC(<DM+;`KL<GJ\17/4JQK\V_C3_P0I_:2^#U[.+;P=:>-
MK"-B$O/#NH13^8/7R93'*/IM/UK^AFBOL,KXXS3!05/F4XK92UMZ--/[VS&=
M"$M=C^9$?\$V_P!H0W7D_P#"E/B9YG_8#F"_]]8V_K7KGP3_`."#W[2'QAO8
M?MWA2P\#:?(1ON_$.H1QM&/40PF24GV(7ZBOZ$J*]>OXF9A*-J=.$7WU?Z_Y
MD+"QZL^&?V#?^"$7PQ_9(U:Q\3>*)F^)/C>S(E@NK^W6/3M-D'.Z"VRP+@])
M)"[#@KL-?<U%%?#9AF>*QU7VV*FY2\^GHMDO0WC%15D%5M9TBV\0Z1=Z?>PI
M<V=]"]O/$_W98W4JRGV()%6:*XDVM44>,Q_\$]/@Q#$L:^`=)5$`55$DP4`=
M`!OZ5WDGP.\(2?#:V\'#P]I<?A>T:)H=,BA$5O&8I5E0A5QR)%5L]R,G-=51
M714QN(G;GJ2=M5=MV?<7*ELC!^)'PM\._&#PQ)HOBC1K#7-,D<2&WNXA(JNO
MW74]5<=F4@CL:YCX:?LF?#OX0^)1K6@^&+6WUA(S%'?7$TUY<P(>JQR3.[(#
MT(4C(KT6BHCB:L8.G&347TN[?<#2W.`^)W[+7@#XQ>((]8\0^&;*[UF*,1+J
M,+R6EYL'1#-"R2%1V!;`J_\`"CX!>#_@?'>CPMH-II4NI,K7=P"\US=%?N^9
M-(6D<#)P&8@9.*["BF\56</9.;Y>UW;[@LKWL>7^.?V,/AC\1O%-WK>J^$[1
MM4U`[KRXM+B>R:]/K,(702G'=P2:ZK2_@SX5T/X:3^#;+0-+LO"]S:R6<NF6
M\`BMY(I%*R*57&=P)R>IR23FNFHIRQ5:45&4VTMM7IZ!9=CCOB#^S_X-^*O@
MW3?#WB'0++5-&T=XY+*UEW!+9HT,:%<$$$(2!ST-<WX6_8B^%7@GQ+8:SI?@
MW3K/4]+G6YM9TEF+0R+T89<C(]Q7JM%..,KQCR1FTNUW;4&EV,G3/`FD:-XO
MU77[6P@AUG6XH(+Z[4'S+E(0XB5O9=[X_P!XU0L_@[X7T_XHW7C:#0]/A\67
MUF-/N-4CCVW$\`*D(Y'W@"J\GG"@9P!72T5E[6>NKU5M^G;T\AG`?%/]EOP#
M\:=<AU3Q'X;M+W5H(_)2_AEEM+OR_P"X9H61RO\`LEB/:M;X6?!+PG\$]%GT
M_P`*Z#I^BVUT_FW'D)F2Y?\`OR2-EY&QW8DUU-%7+$UG#V3F^7M=V^X5E>YX
MVO\`P3X^#*9"^`=)0$DX6291DG)X#XZUT^J?LO?#[7/AG8>#KWPGI%YX;TIB
M]E93QF06;%BQ>-R=Z-EF^96!Y/-=[15SQV)E9RJ2=M5J]&'*NQYIX$_8^^''
MPW\56NN:7X9A_M>P!%I=7EU<7TEID8)B,[OY9QQE,''%>ET45E5KU*KYJDG)
8^;N-)+8****R`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
